Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Left ventricular myocardial crypts: morphological patterns and prognostic implications

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Left ventricular trabeculation and major adverse cardiovascular events: the Copenhagen General Population Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Atrial fibrillation (AF) in heart failure (HF) patients has been associated with a worse outcome. Similarly, excessive supraventricular ectopic activity (ESVEA) has been linked to development of AF, stroke and death. This study aimed to investigate AF and ESVEA's association with outcomes and effect of prophylactic implantable cardioverter defibrillator (ICD) implantation in non-ischemic HF patients.

METHODS: A total of 850 patients with non-ischemic HF, left ventricle ejection fraction ≤35%, and elevated N-terminal pro-brain natriuretic peptides underwent 24-hours Holter recording. The presence of AF (≥30 seconds) and ESVEA (≥30 supraventricular ectopic complexes (SVEC) per hour or run of SVEC ≥20 beats) were registered. Outcomes were all-cause mortality, cardiovascular death (CVD) and sudden cardiac death (SCD).

RESULTS: AF was identified in 188 patients (22%), and ESVEA in 84 patients (10%). After 4 years and 11 months of follow-up, a total of 193 patients (23%) had died. AF was associated with all-cause mortality (HR 1.44; CI 1.04-1.99; P=0.03) and CVD (HR 1.59; CI 1.07-2.36; P=0.02). ESVEA was associated with all-cause mortality (HR 1.73; CI 1.16-2.57; P=0.0073) and CVD (HR 1.76; CI 1.06-2.92; P=0.03). Neither AF nor ESVEA was associated with SCD. ICD implantation was not associated with an improved prognosis for neither AF (P-value for interaction=0.17), nor ESVEA (P-value for interaction=0.68).

CONCLUSION: Both AF and ESVEA were associated with worsened prognosis in non-ischemic HF. However, ICD implantation was not associated with an improved prognosis for either group.

OriginalsprogEngelsk
TidsskriftAmerican Heart Journal
Vol/bind232
Sider (fra-til)61-70
Antal sider10
ISSN0002-8703
DOI
StatusUdgivet - 2020

ID: 61235275